Compare Cloudflare Inc (NET) vs TG Therapeutics Inc (TGTX) Price & Performance

Cloudflare (NET) trades at $310.91, up 0.16% with strong technical momentum and bullish moving averages. The company shows robust revenue growth (36% in Q2 2026) and expanding gross margins (72.58%), though it remains unprofitable with a -8.21% net margin. Recent news highlights AI-driven demand and a $2.175 billion convertible note offering, while analyst consensus remains strongly bullish with a $337.10 price target.

The outlook remains positive given strong execution and AI tailwinds, but investors face risks from premium valuation (P/S 42.99), ongoing losses, and competitive pressures. Institutional sentiment is supportive with 72.5% buy ratings, though the stock's proximity to all-time highs warrants caution amid elevated expectations.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.